Leonardo Borregales, MD
Urology · Miami Beach, FLNPI 1316391105
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Angiodynamics, Inc. at 29.4% of the total. 2025 is the largest year on record at $3,952, 4.2 times the $933 reported in 2023.
Across 92 payments — averaging $87.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$2K
- Avyxa Pharma, LLC$2K
- Myriad Genetic Laboratories, Inc.$456
- Koelis Inc.$397
- Ferring Pharmaceuticals Inc.$373
- Urogen Pharma, Inc.$323
- plus $2K from 25 others
Across 1 payment — averaging $1056.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ferring Pharmaceuticals AS$1K
What the payments were for
- Speaking & faculty fees$2,00025%
- Travel & lodging$1,93324%
- Food & beverage$4,08451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 13 | $2,356 |
| Avyxa Pharma, LLC | 4 | $2,345 |
| Myriad Genetic Laboratories, Inc. | 7 | $456 |
| Koelis Inc. | 4 | $397 |
| Ferring Pharmaceuticals Inc. | 10 | $373 |
| Urogen Pharma, Inc. | 4 | $323 |
| Photocure Inc | 1 | $198 |
| Johnson & Johnson | 8 | $196 |
| Olympus America Inc. | 2 | $158 |
| Immunitybio, Inc. | 1 | $146 |
| Boston Scientific | 2 | $131 |
| Baxter Healthcare | 1 | $119 |
| Pfizer | 6 | $112 |
| Axonics, Inc. | 2 | $104 |
| AbbVie | 5 | $90 |
| Agiliti Surgical, Inc. | 1 | $57 |
| Laborie Medical Technologies Corp. | 2 | $52 |
| Lexicon Pharmaceuticals, Inc. | 2 | $51 |
| Sumitomo Pharma America, Inc. | 3 | $50 |
| Bayer | 2 | $48 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Philips North America LLC | 2 | $28 |
| Dendreon Pharmaceuticals LLC | 1 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Verity Pharmaceuticals Inc. | 1 | $22 |
| AstraZeneca | 1 | $22 |
| Novartis | 1 | $21 |
| Ambu Inc. | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Amgen | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanoknife$2,206
- Prolaris$355
- JELMYTO$281
- Cysview$198
- ADSTILADRIN$162
- TRINITY$154
- ANKTIVA$146
- Gyrus ACMI$146
- Soltive$146
- TISSEEL$119
- GreenLight XPS$100
How this compares
$8,018 in reported general payments places this provider in the 70th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 20 | $15,339 |
| Tamsulosin Hcl | 185 | $1,415 |
| Tadalafil | 18 | $682 |
| Ciprofloxacin Hcl | 61 | $281 |
| Finasteride | 27 | $207 |
| Oxybutynin Chloride ErOxybutynin Chloride | 22 | $193 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $106 |
| Sildenafil Citrate | 12 | $53 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $50 | $15,33920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 935 urology providers in Florida.
Other urology in Miami Beach
- Alan NiederMiami Beach$45K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
- Michael McDonaldCelebration$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.